Picture of Matinas BioPharma Holdings logo

MTNB Matinas BioPharma Holdings Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapNeutral

Annual cashflow statement for Matinas BioPharma Holdings, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2021
December 31st
2022
December 31st
2023
December 31st
2024
December 31st
2025
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-23.3-21-22.9-24.3-10.3
Depreciation
Deferred Taxes
Non-Cash Items6.256.275.68.214.81
Unusual Items
Other Non-Cash Items
Changes in Working Capital1.53-4.791.67-0.131-1.51
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Cash from Operating Activities-15.2-19.2-15.3-15.9-7.01
Capital Expenditures-0.26-0.892-0.218
Purchase of Fixed Assets
Other Investing Cash Flow Items175.7713.59.210.335
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities16.84.8813.29.210.335
Financing Cash Flow Items-0.029
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities6.960.079-0.0079.173.39
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash8.51-14.2-2.042.5-3.29